6W2-25725-05050
4 vaccinations
3 coded responses
45 check-ins
3 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 217 / MD
- Registered
- 2021-03-30
- Relationship
- Self
- Race
- Black or African American
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-30
Registered in v-safe
-
2021-03-30
Dose 1 — Pfizer-BioNTech
- 2021-03-30
-
2021-03-31
Health check-in — days 1–6 daily, dose 1Feeling: Fair · Site: Pain · Fatigue or tirednessAdult check-in
- 2021-04-01
- 2021-04-02
- 2021-04-04
-
2021-04-05
Health check-in — days 1–6 daily, dose 1Feeling: Poor · Chills, Headache, Fatigue or tiredness, Nausea, DiarrheaAdult check-in
- 2021-04-06
- 2021-04-13
-
2021-04-20
Dose 2 — Pfizer-BioNTech
- 2021-04-20
-
2021-04-21
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Fever · Chills, Headache, Muscle or body aches, Fatigue or tiredness, Diarrhea · Be unable to work, Be unable to do your normal daily activitiesAdult check-in
- 2021-04-22
- 2021-04-23
- 2021-04-25
- 2021-04-26
- 2021-04-27
- 2021-05-06
- 2021-05-11
- 2021-05-18
- 2021-05-25
- 2021-06-01
- 2021-07-21
- 2021-10-19
-
2021-11-13
Dose 3 — Pfizer-BioNTechCo-administered: Flu
-
2021-11-14
Health check-in — days 1–6 daily, dose 3Feeling: Poor · Site: Pain · Fever · Chills, Headache, Muscle or body aches, Fatigue or tirednessAdult check-in
- 2021-11-15
- 2021-11-16
- 2021-11-17
- 2021-11-18
- 2021-11-27
- 2021-12-06
- 2021-12-13
- 2021-12-18
- 2021-12-27
- 2022-02-14
-
2022-05-15
Survey response — 6 months, dose 3MedDRA: Cough, Headache, Pain, Pyrexia, SARS-CoV-2 test positive, Sensitive skin — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Headache, fever, cough, body aches, skin sensitivity, positive covid testMedDRA releases: 2024-11 · check-in free text available
-
2022-09-18
Dose 4 — Pfizer-BioNTech
-
2022-09-18
Health check-in — day 0, dose 4Feeling: Fair · Site: Pain · Chills, Fatigue or tirednessAdult check-in
-
2022-09-19
Health check-in — days 1–6 daily, dose 4Feeling: Fair · Site: Pain, Swelling · Chills, Headache, Muscle or body aches, Fatigue or tiredness, Diarrhea · Be unable to work or attend school, Be unable to do your normal daily activitiesAdult check-in
-
2022-09-20
Health check-in — days 1–6 daily, dose 4Feeling: Good · Site: Pain, Swelling, Itching · NoneAdult check-in
- 2022-09-24
- 2022-09-25
- 2022-10-02
- 2022-10-16
-
2022-10-23
Survey response — day 35, dose 4MedDRA: Heavy menstrual bleeding, Menstrual disorder — Feeling: Good · Be unable to do your normal daily activitiesFree text: Changes in menstrual cycle. Excessively heavy flow.MedDRA releases: 2024-11 · check-in free text available
- 2022-11-01
-
2022-12-18
Survey response — 3 months, dose 4MedDRA: Chills, Cough, Oropharyngeal pain, Pain, Respiratory tract congestion, Respiratory tract infection — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Persistent cough (multiple weeks), Respiratory infection, sore throat, aches, chills, congestionMedDRA releases: 2024-11 · check-in free text available
-
2022-12-18
Report sent to call center — 3 months, dose 4Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2022-12-20
- 2023-03-19
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-30 | Pfizer-BioNTech | |
| 2 | 2021-04-20 | Pfizer-BioNTech | |
| 3 | 2021-11-13 | Pfizer-BioNTech | Flu |
| 4 | 2022-09-18 | Pfizer-BioNTech | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-12-18 | Unsuccessful |
Free text
Release 11 — 6 months, dose 3
Symptoms: Headache, fever, cough, body aches, skin sensitivity, positive covid test
Release 12 — day 35, dose 4
Symptoms: Changes in menstrual cycle. Excessively heavy flow.
Release 12 — 3 months, dose 4
Symptoms: Persistent cough (multiple weeks), Respiratory infection, sore throat, aches, chills, congestion
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Chills | · | · | ✓ |
| SD | Cough | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Heavy menstrual bleeding | · | · | ✓ |
| SD | Menstrual disorder | · | · | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Pain | · | · | ✓ |
| SD | Pyrexia | · | · | ✓ |
| SD | Respiratory tract congestion | · | · | ✓ |
| SD | Respiratory tract infection | · | · | ✓ |
| SD | SARS-CoV-2 test positive | · | · | ✓ |
| SD | Sensitive skin | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release